Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high ... Immunotherapy treatments, like Keytruda ...

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer ... the Keytruda-pemetrexed-platinum chemotherapy combination significantly improved overall survival ...

The FDA has approved Merck's Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer ... response rates and progression-free survival data ...

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

However, therapies for stage III lung cancer are improving, and survival rates have gotten better in recent years. How long can you live with stage III lung cancer? Everyone's outlook is different ...

No treatment for lung cancer today gives us significantly better chances of survival than chest surgery from 60 years ago, according to a medical historian from The University of Manchester. Dr ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda ... and overall survival compared to placebo in patients with previously untreated, resectable NSCLC. Benson Fayehun, head of oncology ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

MSD Research Laboratories oncology and global clinical development senior vice-president and head Dr Marjorie Green said: “While the overall survival rates ... Keytruda combination for lung ...